findmyKOL
Clinical trialNCT05003141UnknownPhase 1Interventional

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

SponsorQilu Puget Sound Biotherapeutics (dba Sound Biologics)Enrollment110Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFollicular LymphomaIndolent LymphomaMALT LymphomaMantle Cell LymphomaMarginal Zone Lymphoma+2 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Product: PSB202 is a novel biological entity consisting of two engineered monoclonal antibodies, an Fc-enhanced humanized type II anti-CD20 IgG1 (PSB102) and a humanized anti-CD37 IgG1 (PSB107), that target B-cells. PSB202 is manufactured to work as a single product with the two components of PSB202 enabling a distinct dual target-specific antibody directed cell killing of B-cells. Study: Multi-center-, International Phase 1a/1b (Escalation/Expansion) study in patients with indolent-, relapsed-, B-cell malignancies. The Phase 1a (Dose Escalation) part of study follows a 3+3 design.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Epworth Healthcare

    East Melbourne, Victoria, Australia

    Recruiting
  • One Clinical Research

    Perth, Western Australia, Australia

    Recruiting
China
  • Ruijin Hospital

    Shanghai, China

    Recruiting
United States
  • Norton Cancer Institute

    Louisville, Kentucky, United States

    Recruiting
  • Memorial Sloan-Kettering Cancer Center

    New York, New York, United States

    Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PSB202
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
15 Nov 2021
Primary completion
31 Jul 2023
Completion
31 Jan 2024
Last update posted
28 Mar 2022
Registered enrollment
110
Registry id
NCT05003141
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.